sorafenib has been researched along with pemetrexed in 12 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (pemetrexed) | Trials (pemetrexed) | Recent Studies (post-2010) (pemetrexed) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 2,469 | 657 | 1,695 |
Protein | Taxonomy | sorafenib (IC50) | pemetrexed (IC50) |
---|---|---|---|
Thymidylate synthase | Escherichia coli | 1.1 | |
Dihydrofolate reductase | Homo sapiens (human) | 4.0309 | |
Dihydrofolate reductase | Lacticaseibacillus casei | 2.3 | |
Thymidylate synthase | Homo sapiens (human) | 8.1787 | |
Dihydrofolate reductase | Escherichia coli K-12 | 2.3 | |
Folate receptor beta | Homo sapiens (human) | 0.2585 | |
Folate receptor alpha | Homo sapiens (human) | 0.2417 | |
Trifunctional purine biosynthetic protein adenosine-3 | Homo sapiens (human) | 0.0342 | |
Bifunctional purine biosynthesis protein ATIC | Homo sapiens (human) | 0.07 | |
Reduced folate transporter | Homo sapiens (human) | 0.0928 | |
Bifunctional dihydrofolate reductase-thymidylate synthase | Toxoplasma gondii | 1.655 | |
Proton-coupled folate transporter | Homo sapiens (human) | 0.0229 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (8.33) | 29.6817 |
2010's | 11 (91.67) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Hanna, N | 1 |
Bernard, S; Chiu, M; Davies, JM; Dees, EC; Dhruva, NS; Hayes, DN; Hilbun, LR; Ivanova, A; Keller, K; Kim, WY; Socinski, MA; Stinchcombe, TE; Walko, CM | 1 |
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Eulitt, P; Fisher, PB; Grant, S; Hamed, HA; Hubbard, N; Moran, RG; Nephew, KP; Park, MA; Tang, Y; Tye, G; Yacoub, A | 1 |
Bareford, MD; Burow, ME; Cruickshanks, N; Dent, P; Fisher, PB; Grant, S; Hamed, HA; Moran, RG; Nephew, KP; Tang, Y | 1 |
Allegood, J; Bareford, MD; Cruickshanks, N; Dent, P; Grant, S; Hamed, HA; Ogretmen, B; Park, MA; Poklepovic, A; Spiegel, S | 1 |
Chen, J; Chen, L; Jiang, Y; Li, C; Li, Y; Ma, Y | 1 |
Barrington, S; Cane, P; Dunn, JT; Lal, R; Landau, D; Lang-Lazdunski, L; McLennan, B; Papa, S; Popat, S; Prevost, AT; Shah, R; Spicer, J; Viney, Z | 1 |
Boone, DL; Booth, L; Chuckalovcak, J; Dent, P; Koromilas, AE; McGuire, WP; Poklepovic, A; Roberts, JL; Stringer, DK; Tavallai, M | 1 |
Booth, L; Bose, P; Dent, P; Geyer, CE; Gordon, S; Kmieciak, M; Massey, HD; McGuire, WP; Moran, RG; Poklepovic, A; Quigley, M; Roberts, JD; Shafer, DA; Shrader, E; Strickler, K; Tombes, MB; Wan, W | 1 |
Booth, L; Dent, P; Poklepovic, A; Roberts, JL | 1 |
1 review(s) available for sorafenib and pemetrexed
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
4 trial(s) available for sorafenib and pemetrexed
Article | Year |
---|---|
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Docetaxel; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Niacinamide; Pemetrexed; Phenylurea Compounds; Piperidines; Probability; Prognosis; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Sorafenib; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
A phase I trial of sorafenib combined with cisplatin/etoposide or carboplatin/pemetrexed in refractory solid tumor patients.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Carboplatin; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; Etoposide; Female; Glutamates; Guanine; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Treatment Outcome | 2011 |
Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Glutamates; Guanine; Humans; Male; Mesothelioma; Middle Aged; Neoplasm Staging; Niacinamide; Pemetrexed; Phenylurea Compounds; Platinum; Pleural Neoplasms; Prognosis; Protein Kinase Inhibitors; Salvage Therapy; Sorafenib; Survival Rate | 2013 |
Phase I study of pemetrexed with sorafenib in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cohort Studies; Female; Humans; Inflammation; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; PTEN Phosphohydrolase; Sorafenib; Treatment Outcome; Triple Negative Breast Neoplasms | 2016 |
7 other study(ies) available for sorafenib and pemetrexed
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Benzenesulfonates; Cell Line, Tumor; Drug Synergism; Female; Glutamates; Guanine; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasms; Niacinamide; Pemetrexed; Phenylurea Compounds; Pyridines; Sorafenib; Tissue Distribution | 2011 |
Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells.
Topics: Animals; Antineoplastic Agents; Autophagy; Benzenesulfonates; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Gene Expression Regulation, Neoplastic; Glutamates; Guanine; Humans; Liver Neoplasms; Mice; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Sorafenib | 2011 |
Sorafenib and pemetrexed toxicity in cancer cells is mediated via SRC-ERK signaling.
Topics: Antineoplastic Agents; Autophagy; Benzenesulfonates; Breast Neoplasms; Cell Line, Tumor; Drug Synergism; Endosomes; Enzyme Activation; Extracellular Signal-Regulated MAP Kinases; Female; Gene Knockdown Techniques; Glutamates; Guanine; Humans; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein Phosphatase 2; Pyridines; Receptor, Platelet-Derived Growth Factor beta; RNA Interference; Sorafenib; src-Family Kinases | 2012 |
The inhibition of the pemetrexed-activated MAPK pathway via sorafenib is involved in the synergistic mechanism of sorafenib subsequent potentiation of pemetrexed cytotoxicity in EGFR TKI-resistant cell lines.
Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; MAP Kinase Signaling System; Niacinamide; Pemetrexed; Phenylurea Compounds; Protein-Tyrosine Kinases; Pyridines; Sorafenib | 2012 |
[Pemetrexed + Sorafenib] lethality is increased by inhibition of ERBB1/2/3-PI3K-NFκB compensatory survival signaling.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Breast Neoplasms; Cell Proliferation; Drug Synergism; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; NF-kappa B; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphoinositide-3 Kinase Inhibitors; Receptor, ErbB-2; Receptor, ErbB-3; Signal Transduction; Sorafenib; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2016 |
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib].
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Autophagy; Cell Line, Tumor; Drug Synergism; Humans; Lung Neoplasms; Mice; Neoplasms, Experimental; Niacinamide; Pemetrexed; Phenylurea Compounds; Phosphodiesterase 5 Inhibitors; Sildenafil Citrate; Sorafenib; Xenograft Model Antitumor Assays | 2017 |